Characteristics of responders to autologous bone marrow cell therapy for no-option critical limb ischemia
© The Author(s). 2016
Received: 21 March 2016
Accepted: 27 July 2016
Published: 17 August 2016
The present study investigated factors associated with therapeutic benefits after autologous bone marrow cell (BMC) therapy in patients with “no-option” critical limb ischemia (CLI).
Methods and results
Sixty-two patients with advanced CLI (Rutherford category 5 or 6) not eligible for revascularization were randomized to treatment with 40 ml of autologous BMCs (SmartPreP2) by local intramuscular (n = 32) or intra-arterial (n = 30) application. The primary endpoint was limb salvage and wound healing at 12 months. Seven patients (11 %) died during the follow-up from reasons unrelated to stem cell therapy. The BMC product of patients with limb salvage and wound healing (33/55) was characterized by a higher CD34+ cell count (p = 0.001), as well as a higher number of total bone marrow mononuclear cells (BM-MNCs) (p = 0.032), than that of nonresponders (22/55). Patients with limb salvage and wound healing were younger (p = 0.028), had lower C-reactive protein levels (p = 0.038), and had higher transcutaneous oxygen pressure (tcpO2) (p = 0.003) before cell application than nonresponders. All patients with major tissue loss at baseline (Rutherford 6 stage of CLI, n = 5) showed progression of limb ischemia and required major limb amputation. In the multiple binary logistic regression model, the number of applied CD34+ cells (p = 0.046) and baseline tcpO2 (p = 0.031) were independent predictors of limb salvage and wound healing. The number of administrated BM-MNCs strongly correlated with decreased peripheral leukocyte count after 6 months in surviving patients with limb salvage (p = 0.0008).
Patients who benefited from autologous BMC therapy for “no-option” CLI were treated with high doses of CD34+ cells. The absolute number of applied BM-MNCs correlated with the improvement of inflammation. We hypothesize that the therapeutic benefit of cell therapy for peripheral artery disease is the result of synergistic effects mediated by a mixture of active cells with regenerative potential. Patients at the most advanced stage of CLI do not appear to be suitable candidates for cell therapy.
The study was approved and registered by the ISRCTN registry. Trial registration: ISRCTN16096154. Registered: 26 July 2016.
KeywordsCritical limb ischemia Angiogenesis Stem cells Inflammation Limb salvage
Cell therapy is emerging as an alternative strategy for the treatment of patients with critical limb ischemia (CLI) who are not eligible for endovascular or surgical revascularization. Several preclinical and clinical studies suggest that delivery of progenitor stem cells improves blood circulation and tissue perfusion, preventing amputation via the induction of capillary or collateral growth in a process called “therapeutic angiogenesis” . Although many cell types have been tested, most clinical trials to date have relied on the use of adult autologous bone marrow-derived mononuclear cells (BM-MNCs) or cultured peripheral blood-derived mononuclear cells [2–4]. Alternatively, mesenchymal stem cells (MSCs) have gained therapeutic interest in interventions aimed at tissue restoration because of their multipotent differentiation capacity and their cytoprotective and imunomodulatory effects [5–8]. The aim of the present study was to address factors associated with the therapeutic benefits of cellular therapy in patients who are not eligible for endovascular or surgical revascularization designated “no-option” CLI.
During the inclusion period of 30 months, 62 patients (age 64 ± 11 years; male:female ratio 54:8) with advanced CLI (Rutherford category 5 or 6) after failed or impossible revascularization were randomized into two groups and treated with 40 ml of bone marrow nucleated cells via the local intramuscular (IM) route (n = 32) or via selective intra-arterial (IA) infusion (n = 30), with equal sex distribution and equal distribution of patients with diabetes in both groups . The etiology of arterial obliteration was atherosclerosis in 56 patients and thromboangiitis obliterans (Buerger disease) in six patients.
(1) Patients older than 18 years with ischemic skin lesions (ulcer or gangrene) with CLI Rutherford category 5 or 6 according to the Transatlantic Inter-Society Consensus (TASC) classification (minor or major tissue loss) , or major tissue loss, defined as necrosis or gangrene extending proximal to the metatarsal line or as extensive deep heel gangrene; (2) CLI, defined by an ankle-brachial index (ABI) ≤0.4 or ankle systolic pressure <50 mmHg, or toe systolic pressure <30 mmHg, and transcutaneous oxygen pressure (tcpO2) <30 mmHg; (3) no option for endovascular or surgical revascularization as determined by both vascular surgeon and interventionalist; and (4) failed revascularization, defined as no change of clinical status with the best standard care 4 weeks after endovascular or surgical revascularization.
(1) Life expectancy of <6 months; (2) evidence of malignancy during the last 5 years; (3) critical coronary artery disease or unstable angina pectoris; (4) end-stage kidney disease and patients on dialysis; and (5) bone marrow disease (e.g., myelodysplastic syndrome, severe anemia, leucopenia, thrombocytopenia).
Bone marrow cell isolation and administration
Isolation of stem cells was performed under analgosedation with propofol. A total of 240 ml of bone marrow from both posterior iliac crests was harvested. Bone marrow aspirates were processed with the SmartPreP2 Bone Marrow Aspirate Concentrate System (Harvest, Plymouth, MA, USA). This system uses gradient density centrifugation to provide 40 ml of bone marrow product enriched in all blood elements within 15 minutes [11, 12]. Immediately after stem cell harvest and centrifugation, the bone marrow cell (BMC) concentrate was administered either by IM application (under analgosedation with propofol by deep IM injections into the muscles of the affected limb along the crural arteries, with approximately 1 ml for each injection) or by IA infusion (injection of 40 ml of BMC using a percutaneous femoral approach with a 4 F catheter at the site of arterial occlusion of the affected limb, at a rate of 800 ml/hour).
Preprocedure assessment and follow-up
All patients were examined before and at 90 days, 6 months, and 12 months after BMC delivery. Peripheral blood tests such as blood count and basal serological parameters including C-reactive protein (CRP) were assessed. The total concentration of mononuclear cells (BM-MNCs) and CD34+ cells in bone marrow concentrates was evaluated. Soluble forms of the cell adhesion molecules, markers for vascular endothelial activation or injury (sE-selectin, sP-selectin, sICAM-1, sICAM-3, sPECAM-1), and vascular endothelial growth factor (VEGF) levels were determined in a subgroup of 45 patients in peripheral blood samples using commercially available enzyme immunoassay (ELISA) kits (Adhesion 6-plex and FlowCytomix™ Kits; eBioscience, Austria; VEGF-A Platinum ELISA; Bender MedSystems GmbH, Austria).
Measurement of the resting ABI was performed according to validated standards . The tcpO2 of the affected limb was assessed using a TCM400 Mk2 monitor (Radiometer Medical ApS, Copenhagen, Denmark). The tcpO2 was measured at the forefoot in the supine position with an electrode temperature of 44 °C. Wound characteristics were documented by digital photography. Wound healing was evaluated by two independent physicians. Pain was assessed using a visual analog scale graded from 0 to 10. Patients were discharged the day after the procedure on dual antiplatelet therapy (aspirin and clopidogrel) and statin therapy. All patients received conventional wound care during follow-up.
The primary endpoint was limb salvage and wound healing at 12 months of follow-up. Surviving patients with limb salvage and wound healing were considered responders to BMC therapy. Patients requiring major limb amputation or those with no signs of wound healing were considered nonresponders. Secondary endpoints were mortality, amputation-free survival (AFS), major limb amputation, change in tcpO2, Rutherford category, and pain scale after BMC transplantation.
Data analysis was performed using the statistical software package SPSS 13.0 (SPSS Inc., Chicago, IL, USA). Discrete variables are presented as counts and percentages. Continuous variables are presented as mean values ± SD. Gaussian distributions of data were tested with the Kolmogorov–Smirnov test. A paired t test was used to compare values before and after BMC transplantation. The difference in interval variables between two outcome groups was investigated in univariate analysis by two-way, independent-samples Student t test (for equal variances) or Welch t test (for unequal variances). For categorical variables, the chi-square test was performed. Subsequently, multiple binary logistic regression analysis was used to study predictors of clinical benefit after BMC application. For all analyses, p <0.05 was considered statistically significant.
Main results: 12-month follow-up after bone marrow cell application (n = 62)
7/62 (11 %)
39/62 (63 %)
39/55 (71 %)
Limb salvage + wound healing
33/55 (60 %)
Characteristics of patients with limb salvage and wound healing
Characteristics of patients before bone marrow cell application
All patients (n = 62)
Limb salvage and wound healing (n = 33)
Major limb amputation or nonhealing ulcer (n = 22)
64 ± 11
60 ± 11
66 ± 9
8 (13 %)
4 (12 %)
4 (18 %)
Mode of administration (IM)
32 (52 %)
18 (55 %)
11 (50 %)
41 (66 %)
21 (64 %)
15 (68 %)
48 (77 %)
22 (67 %)
19 (86 %)
32 (52 %)
18 (55 %)
12 (55 %)
Obesity (BMI > 30)
12 (19 %)
8 (24 %)
3 (14 %)
25 (40 %)
16 (48 %)
7 (32 %)
Soluble creatinine (μmol/l)
95 ± 47
90 ± 40
91 ± 20
25 ± 51
11 ± 18
48 ± 77
9.1 ± 4.7
8.8 ± 5.2
9.4 ± 4.2
Rutherford category 6b
5.1 ± 0.3
0 (0 %)
5 (23 %)
0.8 ± 0.4
0.8 ± 0.3
0.7 ± 0.5
tcpO2 baseline (mmHg)
14 ± 10
16 ± 10
9 ± 8
Pain scale (0–10)
4.7 ± 2.4
4.1 ± 2.5
5.7 ± 1.5
3.9 ± 0.9
3.7 ± 0.9
4.1 ± 0.9
4.3 ± 1.1
4.4 ± 1.1
4.3 ± 0.9
17 ± 13
18 ± 10
15 ± 17
4.2 ± 1.4
4.5 ± 1.4
3.8 ± 1.2
28 ± 16
34 ± 19
20 ± 10
6 (10 %)
6 (18 %)
Parameters of limb ischemia after BMC delivery in patients with limb salvage (n = 39)
6-month follow up
12-month follow up
5.0 ± 0
3.9 ± 1.3
3.1 ± 1.4
16 ± 10
30 ± 14
27 ± 14
0.8 ± 0.3
0.9 ± 0.3
0.9 ± 0.3
Pain scale (0–10)
4.3 ± 2.4
1.6 ± 1.6
1.1 ± 1.6
56 ± 16
70 ± 11
73 ± 12
Wound size (cm2)
6.5 ± 5.9
3.3 ± 5.1
1.7 ± 2.5
Cell adhesion molecules VEGF concentrations before bone marrow cell application: subgroup analysis (n = 45)
All patients (n = 45)
Surviving patients with limb salvage (n = 31)
Death or major limb amputation (n = 14)
688 ± 287
738 ± 311
569 ± 181
127 ± 76
126 ± 64
129 ± 101
125 ± 53
137 ± 54
98 ± 41
804 ± 620
818 ± 696
771 ± 429
419 ± 151
391 ± 144
481 ± 152
168 ± 183
185 ± 187
130 ± 170
After bone marrow aspiration, no bleeding complications or decrease in blood count requiring substitution therapy emerged. No infection, local swelling, or other adverse effects associated with cell application were observed after IM or IA application. Both IM and IA procedures were well tolerated. There was no evidence of newly diagnosed malignancy or other adverse events possibly associated with cell application during the follow-up period.
The present study investigated factors predictive of the effect of BMC on the progression of advanced CLI. The main findings can be summarized as follows: the number of applied CD34+ cells was an independent predictor of limb salvage and wound healing; the absolute number of applied BM-MNCs correlated with a decrease in the peripheral leukocyte count; and extremely advanced limb malperfusion is associated with lack of therapeutic benefit from BMC therapy.
Despite several studies documenting the positive clinical outcomes of cell therapy in patients with CLI, the role of such therapy remains controversial. This could be due to differences between studies regarding administration route, cell type, cell source, or cell dose. The recent well-designed, randomized, double-blind, placebo-controlled JUVENTAS study  with repetitive IA infusion of autologous BM-MNC in patients with “no-option” CLI did not confirm the reduction of major limb amputation rates after cell application, and a relation between the number of BMCs administered and clinical improvement was not observed. In the present study, however, the number of CD34+ cells in the BMC concentrate was an independent predictor of therapeutic benefit in terms of limb salvage and wound healing after 12 months. Of note, we used higher concentrations of applied mononuclear cells, as well as of CD34+ cells, than the JUVENTAS trial. The surface expression of CD34, CD133, and vascular endothelial growth factor receptor-2 (VEGFR-2/KDR) identifies a population of endothelial progenitor cells (EPCs) with enhanced potency for neovascularization of ischemic tissue [15–17]. The CD34+ cells restored the microcirculation and improved tissue perfusion in preclinical models  as well as in clinical series . In the present study, the total number of nucleated stem cells administered during the procedure strongly correlated with a decrease in the peripheral leukocyte count at the 6-month follow-up. In the PROVASA trial, patients with healing ulcers after IA BM-MNC application had received a greater number of total BM-MNCs, as well as of CD34+ cells. Repeated BM-MNC administration and a greater number of administered BM-MNCs were independent predictors of complete ulcer healing . Our observations were in agreement with the concept that cell therapy for peripheral artery disease benefits from the application of a mixture of active cells with regenerative potential and secretory capacity acting in a synergistic manner. These cells are characterized by their monocytic or MSC phenotype, and act predominantly through the release of angiogenic growth factors [5, 17, 21, 22]. Flow cytometric analysis of standard MSC markers revealed significantly higher expression of CD44 and CD90 in patients with “no-option” CLI and good responses to cell therapy compared with nonresponders . This position is supported by the finding that CD34+-stimulated neovascularization is enhanced by coculture with CD34– cells, including macrophages, monocytes, T cells, B cells, and megakaryocytes . CD34– cells are the key regulators of EPC development and differentiation from CD34+ cells through cell-to-cell interactions and paracrine actions .
MSCs, which are broadly accepted as a crucial regenerative component of BM-MNC concentrate, have been shown to be effective for treating limb ischemia in animal models and human patients [7, 8]. Application of MSCs has been shown to improve wound healing predominantly through paracrine interactions inducing endogenous reparatory processes. Successful wound healing requires cell migration, angiogenesis, granulation tissue formation, re-epithelization, and extracellular matrix remodeling. Angiogenic factors and cytokines secreted by MSCs promote angiogenesis, decrease wound inflammation by their immunomodulatory properties, and enhance regeneration of skin structures. MSCs have been shown to inhibit the expression of matrix metalloproteinase-1, which suggests that MSCs suppress degradation of collagenous matrix and contribute to fibroblast regeneration [4, 7, 8]. In addition, it has been recognized that MSCs released rich secretome together with extracellular exosomes that might be responsible for transfer of regulatory gene products needed for reparatory process induction .
The present data indicate that age is an independent predictor of AFS. Serum levels of sE-selectin, a marker of endothelial activation , were inversely correlated with age. Surviving patients with limb salvage had higher concentrations of both sE-selectin and sICAM-1 than patients with no AFS. Aging affects the number, function, and composition of adult stem cells [27, 28]. Early EPCs (defined as CD34+/KDR+ or CD133+/KDR+) isolated from the peripheral blood of older individuals (average age 61 years) were significantly impaired in terms of proliferation, migration, and survival, compared with those obtained from healthy young subjects (average age 25 years), with no differences in the number of EPCs between the two groups . In addition, an age-related decline in the expression of proangiogenic factors, including growth factors, cytokines, and hormones, is likely to contribute to impaired EPC generation, mobilization, migration, and survival . Aging and aging-related disorders also significantly impair the survival and differentiation potential of BM-MSCs, thus limiting their therapeutic efficacy. Functional impairment of cells in polymorbid patients could be overcome by cell modification (enhancement of cell potency before administration—ex-vivo stimulation, genetic manipulation) or by modification of the recipient environment, and hence improvement of long-term cell retention, engraftment, and survival after transplantation. There is also emerging interest in the identification of alternative cell sources for MSCs. Induced pluripotent stem cells (iPSCs) and allogeneic MSCs may provide an alternative source of functional cells. Patient-specific iPSC-MSCs and allogeneic MSCs from healthy donors can be prepared as an “off-the-shelf” product for the treatment of tissue ischemia [4, 31, 32]. Both fundamental research as well as large randomized trials are needed to further consolidate the evidence.
Finally, the present data also underscore the importance of local ischemia and inflammation in the effects of BMC therapy. The tcpO2, a routinely used parameter of limb perfusion, was an independent predictor of limb salvage and wound healing. In addition, we showed an association between Rutherford stage 6 limb ischemia and a negative therapeutic outcome of cell delivery. This is consistent with the results of the PROVASA trial, where patients with Rutherford class 6 CLI at baseline did not respond to cell therapy . Similarly, Gupta et al.  showed that patients with impending amputation did not derive any benefit from BM-MSC administration. Thus, advanced local inflammation of ischemic tissues likely generates a hostile environment for delivered stem cells. Clinical studies should consider the timing of stem cell therapy with regard to the deleterious inflammatory setting.
The main limitation of the study was the lack of a control group of CLI patients who did not receive BMC application. The absence of a control group does not exclude the possibility of spontaneous healing in some patients. Likewise, a relatively small number of patients in the nonresponder group could cloud the predictive power of the parameters associated with the benefits of stem cell therapy. Accordingly, the current findings provide a mechanistic understanding and are hypothesis generating for future larger and placebo-controlled trials.
Cell therapy holds great promise for the effective treatment of patients with “no-option” CLI and shows a favorable safety profile. A higher concentration of BM-MNCs, especially of CD34+ cells, was associated with the clinical benefit of cell therapy. Conversely, the most advance stage of limb ischemia and pending major limb amputation were associated with a negative clinical response. The outcome of cell therapy is determined by the synergistic effect of various mechanisms mediated by a mixture of active cells, and of trophic factors and cytokines acting in response to ischemia and inflammation in a coordinated fashion. These findings should be considered in the design of larger studies addressing the benefits of cell therapy in a high-risk population of patients with CLI.
ABI, ankle-brachial index; AFS, amputation-free survival; BMC, bone marrow cell; BM-MNC, bone marrow-derived mononuclear cell; CI, confidence interval; CLI, critical limb ischemia; CRP, C-reactive protein; EPC, endothelial progenitor cell; E-selectin, endothelial–leukocyte adhesion molecule; IA, intra-arterial; ICAM, intercellular adhesion molecule; IM, intramuscular; iPSC, induced pluripotent stem cell; MSC, mesenchymal stem cell; PECAM, platelet endothelial cell adhesion molecule; tcpO2, transcutaneous oxygen pressure; VEGF, vascular endothelial growth factor; P-selectin, platelets activating adhesion molecule
This study was sponsored by a grant from European Regional Development Funding (ITMS code: 26240220023).
Availability of data and materials
The dataset supporting the conclusions of this article is included (Additional file 1).
JM wrote the manuscript, and designed and coordinate the study. JM, AK, MV, MM, MB, RN, TM, and IV were responsible for acquisition and interpretation of the data. LP was responsible for statistical analysis. AK, IV, JM, and RN were responsible for angiography and indications. MM, AK, JM, and IO were responsible for stem cell isolation and administration. MV, MM, and MB were responsible for laboratory analyses. TM, JM, and RN were responsible for follow-up. All authors critically read and approved the final manuscript.
The authors declare that they have no financial or nonfinancial competing interests.
Ethics approval and consent to participate
The study design was approved by the local Ethics Committee of the National Institute of Cardiovascular Diseases, Bratislava. All included patients were informed about the nature of the study and gave their written informed consent.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S, Masaki H, Amano K, Kishimoto Y, Yoshimoto K, Akashi H, Shimada K, Iwasaka T, Imaizumi T, Therapeutic Angiogenesis using Cell Transplantation (TACT) Study Investigators. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet. 2002;360:427–35.View ArticlePubMedGoogle Scholar
- Benoit E, O'Donnell TF, Patel AN. Safety and efficacy of autologous cell therapy in critical limb ischemia: a systematic review. Cell Transplant. 2013;22:545–62.View ArticlePubMedGoogle Scholar
- Teraa M, Sprengers RW, van der Graaf Y, Peters CE, Moll FL, Verhaar MC. Autologous bone marrow-derived cell therapy in patients with critical limb ischemia: a meta-analysis of randomized controlled clinical trials. Ann Surg. 2013;258:922–9.View ArticlePubMedGoogle Scholar
- Compagna R, Amato B, Massa S, Amato M, Grande R, Butrico L, de Franciscis S, Serra R. Cell therapy in patients with critical limb ischemia. Stem Cells Int. 2015;2015:931420.View ArticlePubMedPubMed CentralGoogle Scholar
- Lu D, Chen B, Liang Z, Deng W, Jiang Y, Li S, Xu J, Wu Q, Zhang Z, Xie B, Chen S. Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial. Diabetes Res Clin Pract. 2011;92:26–36.View ArticlePubMedGoogle Scholar
- Altaner C, Altanerova V, Cihova M, Hunakova L, Kaiserova K, Klepanec A, Vulev I, Madaric J. Characterization of mesenchymal stem cells of “no-options” patients with critical limb ischemia treated by autologous bone marrow mononuclear cells. PLoS One. 2013;8:e73722.View ArticlePubMedPubMed CentralGoogle Scholar
- Liew A, O'Brien T. Therapeutic potential for mesenchymal stem cell transplantation in critical limb ischemia. Stem Cell Res Ther. 2012;3:28.View ArticlePubMedPubMed CentralGoogle Scholar
- Lee DE, Ayoub N, Agrawal DK. Mesenchymal stem cells and cutaneous wound healing: novel methods to increase cell delivery and therapeutic efficacy. Stem Cell Res Ther. 2016;7:37.View ArticlePubMedPubMed CentralGoogle Scholar
- Klepanec A, Mistrik M, Altaner C, Valachovicova M, Olejarova I, Slysko R, Balazs T, Urlandova T, Hladikova D, Liska B, Tomka J, Vulev I, Madaric J. No difference in intra-arterial and intramuscular delivery of autologous bone marrow cells in patients with advanced critical limb ischemia. Cell Transplant. 2012;21:1909–18.View ArticlePubMedGoogle Scholar
- Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, TASC II Working Group, Bell K, Caporusso J, Durand-Zaleski I, Komori K, Lammer J, Liapis C, Novo S, Razavi M, Robbs J, Schaper N, Shigematsu H, Sapoval M, White C, White J, Clement D, Creager M, Jaff M, Mohler 3rd E, Rutherford RB, Sheehan P, Sillesen H, Rosenfield K. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33 Suppl 1:S1–75.View ArticlePubMedGoogle Scholar
- Hermann PC, Huber SL, Herrler T, von Hesler C, Andrassy J, Kevy SV, Jacobson MS, Heeschen C. Concentration of bone marrow total nucleated cells by a point-of-care device provides a high yield and preserves their functional activity. Cell Transplant. 2008;16:1059–69.View ArticlePubMedGoogle Scholar
- Amann B, Luedemann C, Ratei R, Schmidt-Lucke JA. Autologous bone marrow cell transplantation increases leg perfusion and reduces amputations in patients with advanced critical limb ischemia due to peripheral artery disease. Cell Transplant. 2009;18:371–80.View ArticlePubMedGoogle Scholar
- Rutherford RB, Bake JD, Ernst C, Johnston KW, Porter JM, Ahn S, Jones DN. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg. 1997;26:517–38.View ArticlePubMedGoogle Scholar
- Teraa M, Sprengers RW, Schutgens RE, Slaper-Cortenbach IC, van der Graaf Y, Algra A, van der Tweel I, Doevendans PA, Mali WP, Moll FL, Verhaar MC. Effect of repetitive intra-arterial infusion of bone marrow mononuclear cells in patients with no-option limb ischemia: the randomized, double-blind, placebo-controlled Rejuvenating Endothelial Progenitor Cells via Transcutaneous Intra-arterial Supplementation (JUVENTAS) trial. Circulation. 2015;131:851–60.View ArticlePubMedGoogle Scholar
- Kawamoto A, Iwasaki H, Kusano K, Murayama T, Oyamada A, Silver M, Hulbert C, Gavin M, Hanley A, Ma H, Kearney M, Zak V, Asahara T, Losordo DW. CD34-positive cells exhibit increased potency and safety for therapeutic neovascularization after myocardial infarction compared with total mononuclear cells. Circulation. 2006;114:2163–9.View ArticlePubMedGoogle Scholar
- Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, Homma S, Edwards NM, Itescu S. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med. 2001;7:430–6.View ArticlePubMedGoogle Scholar
- Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M, Oz MC, Hicklin DJ, Witte L, Moore MA, Rafii S. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood. 2000;95:952–8.PubMedGoogle Scholar
- Iwasaki H, Kawamoto A, Ishikawa M, Oyamada A, Nakamori S, Nishimura H, Sadamoto K, Horii M, Matsumoto T, Murasawa S, Shibata T, Suehiro S, Asahara T. Dose-dependent contribution of CD34-positive cell transplantation to concurrent vasculogenesis and cardiomyogenesis for functional regenerative recovery after myocardial infarction. Circulation. 2006;113:1311–25.View ArticlePubMedGoogle Scholar
- Saigawa T, Kato K, Ozawa T, Toba K, Makiyama Y, Minagawa S, Hashimoto S, Furukawa T, Nakamura Y, Hanawa H, Kodama M, Yoshimura N, Fujiwara H, Namura O, Sogawa M, Hayashi J, Aizawa Y. Clinical application of bone marrow implantation in patients with arteriosclerosis obliterans, and the association between efficacy and the number of implanted bone marrow cells. Circ J. 2004;68:1189–93.View ArticlePubMedGoogle Scholar
- Walter DH, Krankenberg H, Balzer JO, Kalka C, Baumgartner I, Schlüter M, Tonn T, Seeger F, Dimmeler S, Lindhoff-Last E, Zeiher AM, for the PROVASA Investigators. Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: a randomized-start, placebo-controlled pilot trial (PROVASA). Circ Cardiovasc Interv. 2011;4:26–37.View ArticlePubMedGoogle Scholar
- Hare JM, Traversek JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS, Hermiller Jr JB, Reisman MA, Schaer GL, Sherman W. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol. 2009;54:2277–86.View ArticlePubMedPubMed CentralGoogle Scholar
- Kondo K, Shintani S, Shibata R, Murakami H, Murakami R, Imaizumi M, Kitagawa Y, Murohara T. Implantation of adipose-derived regenerative cells enhances ischemia-induced angiogenesis. Arterioscler Thromb Vasc Biol. 2009;29:61–6.View ArticlePubMedGoogle Scholar
- Rookmaaker MB, Verhaar MC, Loomans CJ, Verloop R, Peters E, Westerweel PE, Murohara T, Staal FJ, van Zonneveld AJ, Koolwijk P, Rabelink TJ, van Hinsbergh VW. CD34+ cells home, proliferate, and participate in capillary formation, and in combination with CD- cells enhance tube formation in a 3-dimensional matrix. Arterioscler Thromb Vasc Biol. 2005;25:1843–50.View ArticlePubMedGoogle Scholar
- Kwon SM, Lee JH, Lee SH, Jung SY, Kim DY, Kang SH, Yoo SY, Hong JK, Park JH, Kim JH, Kim SW, Kim YJ, Lee SJ, Kim HG, Asahara T. Cross talk with hematopoietic cells regulates the endothelial progenitor cell differentiation of CD34 positive cells. PLoS One. 2014;9:e106310.View ArticlePubMedPubMed CentralGoogle Scholar
- Konala VB, Mamidi MK, Bhonde R, Das AK, Pochampally R, Pal R. The current landscape of the mesenchymal stromal cell secretome: a new paradigm for cell-free regeneration. Cytotherapy. 2016;18:13–24.View ArticlePubMedGoogle Scholar
- Frijns CJ, Kappelle LJ, van Gijn J, Nieuwenhuis HK, Sixma JJ, Fijnheer R. Soluble adhesion molecules reflect endothelial cell activation in ischemic stroke and in carotid atherosclerosis. Stroke. 1997;28:2214–8.View ArticlePubMedGoogle Scholar
- Kuranda K, Vargaftig J, de la Rochere P, Dosquet C, Charron D, Bardin F, Tonnelle C, Bonnet D, Goodhardt M. Age-related changes in human hematopoietic stem/progenitor cells. Aging Cell. 2011;10:542–6.View ArticlePubMedGoogle Scholar
- Katsara O, Mahaira LG, Iliopoulou EG, Moustaki A, Antsaklis A, Loutradis D, Stefanidis K, Baxevanis CN, Papamichail M, Perez SA. Effects of donor age, gender, and in vitro cellular aging on the phenotypic, functional, and molecular characteristics of mouse bone marrow-derived mesenchymal stem cells. Stem Cells Dev. 2011;20:1549–61.View ArticlePubMedGoogle Scholar
- Heiss C, Keymel S, Niesler U, Ziemann J, Kelm M, Kalka C. Impaired progenitor cell activity in age-related endothelial dysfunction. J Am Coll Cardiol. 2005;45:1441–8.View ArticlePubMedGoogle Scholar
- Chang EI, Loh SA, Ceradini DJ, Chang EI, Lin SE, Bastidas N, Aarabi S, Chan DA, Freedman ML, Giaccia AJ, Gurtner GC. Age decreases endothelial progenitor cell recruitment through decreases in hypoxia-inducible factor1alpha stabilization during ischemia. Circulation. 2007;116:2818–29.View ArticlePubMedGoogle Scholar
- Lian Q, Zhang Y, Zhang J, Zhang HK, Wu X, Zhang Y, Lam FF, Kang S, Xia JC, Lai WH, Au KW, Chow YY, Siu CW, Lee CN, Tse HF. Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice. Circulation. 2010;121:1113–23.View ArticlePubMedGoogle Scholar
- Bartunek J, Behfar A, Dolatabadi D, Vanderheyden M, Ostojic M, Dens J, El Nakadi B, Banovic M, Beleslin B, Vrolix M, Legrand V, Vrints C, Vanoverschelde JL, Crespo-Diaz R, Homsy C, Tendera M, Waldman S, Wijns W, Terzic A. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol. 2013;61:2329–38. Erratum in: J Am Coll Cardiol. 2013;62:2457–8.View ArticlePubMedGoogle Scholar
- Gupta PK, Chullikana A, Parakh R, Desai S, Das A, Gottipamula S, Krishnamurthy S, Anthony N, Pherwani A, Majumdar AS. A double blind randomized placebo controlled phase I/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia. J Transl Med. 2013;11:143.View ArticlePubMedPubMed CentralGoogle Scholar